Drug-induced hypothyroidism in tuberculosis
Authors:
- Juan Eduardo Quiroz-AldaveJQJuan Eduardo Quiroz-Aldave
- María Del Carmen Durand-VásquezMDMaría Del Carmen Durand-Vásquez
- Elman Rolando Gamarra-OsorioEGElman Rolando Gamarra-Osorio
- Luis Alberto Concepción-UrteagaLCLuis Alberto Concepción-Urteaga
- Samuel Pecho-SilvaSPSamuel Pecho-Silva
- Luis Alejandro Rodríguez-HidalgoLRLuis Alejandro Rodríguez-Hidalgo
- Marcio José Concepción-ZavaletaMCMarcio José Concepción-Zavaleta
- 23 January 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 19 (3) , 199-206
Abstract
Introduction: Adverse reactions to tuberculosis treatment can impact patient adherence and prognosis. Hypothyroidism is a frequent adverse reaction caused using ethionamide, prothionamide, and para-aminosalicylic acid and is often underdiagnosed.Areas covered: We searched Scielo, Scopus, and EMBASE databases, including 67 articles. Antitubercular drug-induced hypothyroidism has a prevalence of 17%. It occurs after 2 to 3 months of treatment and resolves within 4 to 6 weeks after discontinuation. It is postulated to result from the inhibition of thyroperoxidase function, blocking thyroid hormone synthesis. Symptoms are nonspecific, necessitating individualized thyroid-stimulating hormone measurement for detection. Specific guidelines for management are lacking, but initiation of treatment with levothyroxine, as is customary for primary hypothyroidism, is recommended. Discontinuation of antitubercular drugs is discouraged, as it may lead to unfavorable consequences.Expert opinion: Antitubercular drug-induced hypothyroidism is more common than previously thought, affecting one in six MDR-TB patients. Despite diagnostic and treatment recommendations, implementation is hindered in low-income countries due to the lack of certified laboratories. New drugs for tuberculosis treatment may affect thyroid function, requiring vigilant monitoring for complications, including hypothyroidism.Keywords
Funding Information
- No funding
This publication has 58 references indexed in Scilit:
- Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone ReplacementThyroid®, 2014
- Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and ManagementJournal of Clinical and Experimental Hepatology, 2013
- Metabolism of the Antituberculosis Drug EthionamideCurrent Drug Metabolism, 2013
- Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid AssociationEndocrine Practice, 2012
- TSH-CHECK-1 Test: Diagnostic Accuracy and Potential Application to Initiating Treatment for Hypothyroidism in Patients on Anti-Tuberculosis DrugsPLOS ONE, 2012
- Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary RegressionThe Journal of Clinical Endocrinology & Metabolism, 2011
- Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 DeiodinationThe Journal of Clinical Endocrinology & Metabolism, 2010
- Role of iodine in thyroid physiologyExpert Review of Endocrinology & Metabolism, 2010
- Genotype-Phenotype Relationship in Patients with Mutations in Thyroid Hormone Transporter MCT8Endocrinology, 2008
- Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid DiseasesThe Journal of Clinical Endocrinology & Metabolism, 2005